Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results

Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the fourth quarter and year ended December 31, 2017, and provided a business update.

As quoted in the press release:

“In 2017, Corvus continued to make progress in expanding its pipeline of product candidates. We have enrolled more than 235 patients on our Phase 1/1b trial with CPI-444 and met the objectives of the trial, which were to optimize dose and schedule, establish safety and identify efficacy signals in renal cell cancer and non-small cell lung cancer (NSCLC),” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “This now positions us to expand studies in both renal cell cancer and NSCLC using patient selection criteria determined from our initial studies.  These studies will focus on patients who have failed prior therapy with anti-PD-(L)1 antibodies, a situation ideally suited for our drug and representing an unmet need in oncology.  We also plan to begin enrolling patients in our Phase 1/1b trial with our anti-CD73 antibody (CPI-006) in the first quarter of 2018.”

Click here to read the full press release.